Resolutions at Senzime AB’s (publ) annual general meeting

Senzime AB (publ) (the “Company”) held its annual general meeting on May 8, 2018 in the Company’s premises on Ulls väg 29B in Uppsala.

Senzime’s Interim report January – March 2018

Uppsala, May 8, 2018. Senzime AB’s (publ) Interim report for January – March 2018 is now available on the company’s webbsite www.senzime.com.

Senzime ads 6 countries to the TetraGraph distribution network

Press Release: Uppsala, April 25, 2018. Senzime AB (publ) today announced that it signed exclusive distribution agreements for TetraGraph in Belgium, Netherlands, Luxemburg, Austria, Czech Republic and Slovakia.

Senzime’s Annual Report 2017

Press Release: Uppsala, April 17, 2018. Senzime AB’s (publ) annual report for fiscal year 2017 (only in Swedish) is now available on the company’s webbsite www.senzime.com.

Senzime signs distribution agreement in South Korea

Press release: Uppsala, March 19, 2018. Senzime AB (publ) today announced that it signed an exclusive distribution agreement with Unimedics (unimedics.co.kr) for the commercialization of the TetraGraph in South Korea. Compensation will be paid per unit in line with current industry compensation including a minimum guaranteed sale. The registration process is estimated to be finalized during 2019.

Senzime signs additional distribution agreements for the TetraGraph

Press Release: Uppsala, March 7, 2018. Senzime AB (publ) today announced that it signed exclusive distribution agreements for TetraGraph in Spain and Portugal.

Resolutions at Senzime AB’s (publ) extraordinary general meeting

Press release: Senzime AB (publ) held an extraordinary general meeting on March 5, 2018 in the premises of Advokatfirman Lindahl on Vaksalagatan 10 in Uppsala.

Reallocation of certain shareholdings in Senzime AB (publ)

Press Release: Uppsala, February 19, 2018. During the period of 19-23 February 2018, a group of major shareholders, including two who are Board Directors of Senzime AB (publ) ("Senzime", "the Company"), will reallocate certain shareholdings. The shares will be reallocated within the group, without any consideration, as a result of a revised and agreed allocation methodology related to a previously closed acquisition.

Senzime’s Year-end Bulletin 2017

Press release: Uppsala, February 16, 2018. Senzime AB’s (publ) year-end bulletin 2017 is now available on the company’s webbsite www.senzime.com.

Notice of extraordinary general meeting in Senzime AB (publ)

The shareholders in Senzime AB (publ), reg. no. 556565-5734 (the “Company”) are hereby convened to the extraordinary general meeting at 9 AM (local time) on Monday 5 March 2018 in the office of Advokatfirman Lindahl at Vaksalagatan 10, 753 20, Uppsala.

Senzime proposes directed new issue that includes Segulah Venture AB, amounting to a total of SEK 25 million

Press Release: Uppsala, February 16, 2018. Prior to the commercialization of its products, Senzime AB (publ) (”Senzime” or ”the Company”) is proposing a directed new issue to a few strategically important investors, including Segulah Venture AB, with a maximum of 4,166,667 shares at a subscription price of SEK 6 per share, equivalent to a discount of approximately 8 per cent compared to the share weighted average price of the previous 10 trading days. Through the rights issue, the Company will receive SEK 25 million before issue costs.

Senzime signs cooperation agreement with Philips

Press release; Uppsala, January 23, 2018.  Senzime AB (publ) has signed a license and cooperation agreement with Philips to allow the TetraGraph Neuromuscular Monitoring System to communicate with Philips IntelliVue patient monitors worldwide. 

Press release; Senzime receives CE mark approval for the OnZurf Probe

Uppsala, December 18, 2017. Senzime AB (publ) announces that the company has received CE mark approval for the OnZurf Probe, which means that the product now is approved for sale on the European market.

Press release; Senzime receives CE mark approval for the TetraGraph

Uppsala, December 12, 2017.  Senzime AB (publ) announced today that it has received CE mark approval to enable the commercialization of the TetraGraph Neuromuscular Monitoring System. 

Senzime’s Interim report January – September 2017

Uppsala, November 28, 2017. Senzime AB’s (publ) Interim report for January – September 2017 is now available on the company’s webbsite www.senzime.com.

Comparative Investigation of TetraGraph and TOF-Watch SX

Press release Uppsala, 23 October 2017. Dr Réka Nemes at the University of Debrecen, Department of Anesthesiology and Intensive Care, Debrecen, Hungary, reports results from the Comparative Investigation of TetraGraph and TOF-Watch SX. 

Senzime submits 510 (k) application to the FDA

Uppsala, September 25, 2017. Senzime AB (publ) announced today that the company has submitted a 510 (k) application to the US Food and Drug Administration (FDA) for approval of the TetraGraph in the United States. 

Senzime signs distribution agreement for the Swiss market

Uppsala, September 18, 2017. Senzime AB (publ) today announced an exclusive distribution agreement with Leuag AG regarding the Swiss market.

RESOLUTIONS AT SENZIME AB’S (PUBL) EXTRAORDINARY GENERAL MEETING

Senzime AB (publ) (the “Company”) held its Extraordinary General Meeting on September 15, 2017 in the premises of Advokatfirman Lindahl on Vaksalagatan 10 in Uppsala.

Notice of Extraordinary General Meeting of Senzime for the introduction of an employee stock option program

Uppsala, August 31, 2017. Senzime AB (publ) calls for an Extraordinary General Meeting for the introduction of an employee stock option program. The Board proposes that the General Meeting approve resolutions to issue no more than 1,300,000 warrants and to introduce an employee stock option plan. 

Senzime’s Interim report January – June 2017

Uppsala, August 31, 2017. Senzime AB’s (publ) Interim report for January – June 2017 is now available on the company’s webbsite www.senzime.com.

Senzime obtains US patent

Uppsala, August 9, 2017. Senzime AB (publ) is awarded a U.S. patent for its TetraSens disposable electrodes. With its unique design, the TetraSens enables fast application and effective function. The electrodes are used in conjunction with Senzime's neuromuscular monitoring system, the TetraGraph, which contributes to effective, continuous monitoring of patients undergoing anesthesia and surgical muscle relaxation. The TetraGraph, via the interfaced TetraSens electrodes, makes it possible to easily and objectively determine the optimal dose of neuromuscular blocking drugs administered during the procedure, and to establish the appropriate time when it is safe to wake the patient after surgery and allow spontaneous breathing without the help of a ventilator. 

TetraGraph clinical use and comparison presented in ASA abstract

Uppsala, 21 June 2017. Senzime AB (publ) in partnership with Dr Réka Nemes at the University of Debrecen, Department of Anesthesiology and Intensive Care, Debrecen, Hungary, reports results from the Comparative Investigation of TOF-Watch SX and the TetraGraph. 

Senzime receives ISO 13485 certification

Uppsala, June 12, 2017. Senzime AB (publ) has received ISO 13485 certification, which is an important milestone in the CE labeling process for the company's first monitoring products.

Senzime initiates clinical study with CliniSenz System

Uppsala, May 31, 2017. Senzime AB (publ) initiates a clinical trial with CliniSenz for monitoring of tissue lactate levels after surgery in patients with esophageal cancer, a disease that affects approximately 500,000 patients worldwide annually. The current treatment is mostly surgical with risk of multiple operations and increased mortality. With CliniSenz System, it is possible to monitor the healing process after surgery and detect complications at an early stage. The study has been approved by the Ethics Committee and is expected to start in the beginning of June 2017.

Senzime is granted additional patent for OnZurf Probe

Uppsala, 24 May 2017. Senzime AB’s (publ) application regarding a new Swedish patent for OnZurf Probe has been approved, strengthening Senzime’s existing patent portfolio. The Onzurf Probe is a new generation of microdialysis probes that enable organ-specific biological monitoring of various organs such and the bowel, liver and kidney after surgery. The technology makes it possible to monitor the organs’ healing process and to provide early warning signs of complications such as ischemia and anastomotic failure.

Resolutions at Senzime AB’s (publ) Annual General Meeting

Senzime AB (publ) held its annual general meeting on May 23, 2017 in the premises of Advokatfirman Lindahl on Vaksalagatan 10 in Uppsala.

Retransmitting: Senzime’s Interim report January – March 2017

Uppsala, May 23, 2017. Senzime AB’s (publ) Interim report for January – March 2017 is now available on the company’s webbsite www.senzime.com.

Senzime’s Interim report January – March 2017

Uppsala, May 23, 2017. Senzime AB’s (publ) Interim report for January – March 2017 is now available on the company’s webbsite www.senzime.com.

TetraGraph Functionality in Scientific Abstract at IARS, Washington DC

Uppsala, May 5th, 2017.  Senzime AB (publ) today announced that the scientific abstract, “Examining Awake Volunteer Pain Scores and Operator Ease of Use of a Novel Neuromuscular Blockade Monitor” is to be presented at the International Anesthesia Research Society (IARS) meeting in Washington, DC where 1200 anesthesiologists participate.

Senzimes first day of trading on Nasdaq First North

Uppsala, April 11, 2017. Senzime AB (publ) recently completed a rights issue that raised SEK 24.4 million before issue costs. Senzime has applied for listing on Nasdaq First North which has been approved with first day of trading April 11, 2017. Previously Senzime was listed on AktieTorget.

Senzime’s rights issue oversubscribed

The subscription period for Senzime AB (publ)’s rights issue with pre-emption rights for existing shareholders (the "Rights Issue") expired on 28 March 2017 and the company is pleased to announce that there has been large interest in the subscription of shares. The Rights Issue was oversubscribed to approximately 103 percent under the original offer. Thus, the company will raise approximately SEK 24.4 million before issue costs, estimated at SEK 3.1 million.

Publication of prospectus regarding the rights issue in Senzime and application for listing on Nasdaq First North

Uppsala, March 14, 2017. The Board of Senzime AB (publ) ("Senzime") has prepared a prospectus regarding the rights issue that was resolved at the extraordinary general meeting in Senzime on March 3, 2017. The Board of Senzime has also applied for listing on Nasdaq First North, and the first day of trading on Nasdaq First North is expected to be April 11, 2017.

Bulletin from the Extraordinary General Meeting in Senzime AB (publ) – resolution on new issue of shares

The shareholders of Senzime have at the Extraordinary General Meeting on March 3, 2017 resolved, in accordance with the board's proposal, to issue new shares with pre-emption rights for existing shareholders. 

Notice of Extraordinary General Meeting in Senzime AB (publ)

The shareholders in Senzime AB (publ) reg. no. 556565-5734 (the “Company”) are hereby convened to the extraordinary general meeting at 9.30 (local time) on Friday 3 March 2017 in the premises of Advokatfirman Lindahl at Vaksalagatan 10, 753 20, Uppsala.

is planning to carry out a fully underwritten rights issue for further market launches and is taking steps toward listing at Nasdaq First North

Uppsala February 16, 2017. The Board of Senzime AB (publ) proposes that an extra general meeting resolves on a rights issue of approximately SEK 24.4 million before issue costs. The rights issue is fully underwritten by the company's principal owner. The proceeds will be used to enable the commercialization of Senzimes products and strengthen its financial position. Concurrently Senzime is planning a listing at Nasdaq First North.

Senzime signs distribution agreements for the TetraGraph

Uppsala, February 9, 2017. Senzime AB (publ) today announced that it signed exclusive distribution agreements for TetraGraph in the UK, Ireland, Australia and New Zealand.

Senzime reports initial evaluation from the clinical trial at NorthShore in Chicago, USA

Uppsala, January 23, 2017.  Senzime AB (publ) reports initial feedback from the clinical trials at NorthShore University HealthSystem, Chicago, USA, a Teaching Affiliate of the University of Chicago Pritzker School of Medicine. Professor Glenn Murphy is a world-leading clinical investigator and authority in postoperative complications that result from residual neuromuscular block in patients undergoing surgery and general anesthesia. He is the lead investigator of the study that examines the clinical utility of the TetraGraph System, and compares its ease of use, reliability and precision to the TOF-Watch, the former leading neuromuscular monitor that has been discontinued from the market.

Senzime announces the nomination committee for the AGM 2017

Uppsala, January 20, 2017. Senzime announces the nomination committee for the AGM 2017.

Senzime announces that yearend report 2016 to be released February 16, 2017

Uppsala, January 20, 2017. The Board of Senzime has decided that the yearend report is to be released one week earlier than announced.

Senzime reports completion of trial

Uppsala, January 12, 2017.  Senzime AB (publ) reports completion of the initial volunteer study performed at the Mayo Clinic in the USA. The study evaluated the ease of use, required set-up time, and volunteer comfort during testing using Senzime’s patient neuromonitoring system, the TetraGraph.

Senzime launches OnZurf Probe for preclinical use

Uppsala, December 19, 2016. Senzime launches OnZurf Probe for use in preclinical research. Onzurf Probe is a new generation of microdialysis probe (catheter) that allows organ-specific monitoring after surgery on organs such as the esophagus, bowel and liver. Onzurf Probe has a unique mode of attachment to the target organ, allowing easy placement of the microdialysis catheter on the surface of the organ. This non-invasive technique obviates the need for penetrating surgical instruments that can cause tissue trauma and stress during placement of the probe. 

Senzime signs license agreement with Fukuda Denshi

Uppsala, December 5, 2016. Senzime AB (publ) has signed an exclusive licensing agreement with Japanese Fukuda Denshi Co Ltd (“Fukuda”). The agreement gives Fukuda the exclusive right to license and commercialize Senzime’s TetraGraph system in Japan with market launch expected by the end of 2017. Senzime’s management and board expects this 10-year agreement to generate more than SEK 100 million in license revenue related to future milestone payments and royalties.

Senzime to conduct clinical trial at University of Debrecen, Hungary

Uppsala, November 15, 2016: Senzime (publ) launches a clinical study at the University of Debrecen, Hungary. This study will evaluate Senzime’s patient neuromonitoring system called TetraGraph, used during anesthesia. This study is designed to investigate the clinical utility of the system in a total of 40 patients, and will compare its ease of use, reliability and precision to the former leading product, the TOF-Watch, that has been discontinued from the market. Results are scheduled for presentation as early as the first quarter of 2017.

Senzime to conduct clinical trial at NorthShore in Chicago, USA

Uppsala, November 7, 2016: Senzime (publ) launches a clinical study at NorthShore University HealthSystem, Chicago, USA, a Teaching Affiliate of the University of Chicago Pritzker School of Medicine. Professor Glenn Murphy is a world-leading authority and clinical investigator of complications that result from residual neuromuscular block in patients undergoing surgery and general anesthesia.  Professor Murphy will head this clinical investigation of the leading neuromuscular monitoring system, the TetraGraph. This study is designed to investigate the clinical utility of the TetraGraph System in a total of 150 patients, and will compare its ease of use, reliability and precision to the former leading product that has been discontinued from the market.

Senzime to conduct studies at Mayo Clinic, US

Uppsala, November 1, 2016. Senzime (publ) is initiating a series of clinical studies to be performed at Mayo Clinic, USA. The studies are intended to evaluate Senzime’s patient neuromonitoring system called TetraGraph, used during anesthesia. Data about the monitor’s ease of clinical use, form factor, design, and ease of set-up will be collected. The clinical validation studies at Mayo Clinic are intended to compare its usability to that of the now-discontinued former market leading monitoring system. Results are scheduled for presentation as early as December 2016.

New Swedish registry study

Uppsala, 12 October 2016. New Swedish registry study – a national collaboration between Senzime, Swedish Medtech, Skåne University Hospital in Lund and University of Gothenburg and the national quality registry for esophageal and gastric cancer.  A clinical trial investigating the OnZurf Probe for continuous, organ specific monitoring of lactate trends in postoperative esophageal cancer patients is ongoing in Lund. Esophageal cancer is a worldwide disease that affects about 500 000 patients annually.  The clinical trial is being expanded in order to examine how the new OnZurf Probe solution may mitigate the healthcare costs associated with this disease. The results from the expanded study are expected to be published in the second quarter of 2017.

Summary of Interim Report January – June, 2016

“We’re building a new global leader in the field of patient monitoring”

Senzime in collaboration with Örebro University

Uppsala, August 25, 2016. Örebro University has been awarded SEK 11 million and will together with Senzime, Sandvik, Techtum and Nanoxis explore why the immune system reacts differently in different people after an operation, during an infection or because of polluted air.

The Board of Senzime has decided that the half-year financial report is postponed to August 31, 2016.